Apr 13th, 2021 - Hydroxychloroquine use in COVID-19 patients was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk for hydroxychloroquine interactions with comorbidities and co-medications contributing to detrimental, including fatal adverse treatment effects. This is a retrospective survey of health conditions and co-medications of COVID-19 patients who were pre-scr...

Apr 12th, 2021 - to investigate prevalence of COVID-19 cases and seroprevalence among rheumatologic patients and the risk factors for infection. a cross sectional study in a rheumatologic population .An online questionnaire was sent on 31st April 2020. Blood Samples from 20% sample of patients were drawn for SARS-CoV-2 antibodies. Patients were divided based on autoimmune (AI) diagnosis. Prevalence of COVID-19 ...

Apr 10th, 2021 - COVID-19 can be asymptomatic in a substantial proportion of patients. The assessment and management of these patients constitute a key element to stop dissemination. To describe the assessment and treatment of asymptomatic infection in patients with a confirmed diagnosis of COVID-19. We searched five databases and search engines for preprints/preproofs, up to August 22, 2020. We included cohort...

Apr 9th, 2021 - To estimate the incidence rate ratio (IRR) of adverse events (AE) in chloroquine or hydroxychloroquine users. We systematically reviewed randomized controlled trials (RCTs), using MEDLINE (2010-2020) and EMBASE (2010-2020) databases, reporting AE in chloroquine or hydroxychloroquine users during treatment for lupus, rheumatoid arthritis, malaria and COVID-19. The protocol for this systematic re...

Apr 8th, 2021 - Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Coll...

Apr 8th, 2021 - Hydroxychloroquine is not efficacious as post-exposure prophylaxis against coronavirus disease 2019 (COVID-19). It is not known whether as pre-exposure prophylaxis it may prevent COVID-19. To compare the incidence of COVID-19 in Spanish patients with autoimmune rheumatic diseases treated with and without hydroxychloroquine. Retrospective electronic record review, from February 27th to June 21st...

Apr 7th, 2021 - Daily briefing: The evidence is not stacking up for hydroxychloroquine as a treatment for COVID-19.|2021|Graham F,Castelvecchi D,Phillips N,|

Apr 5th, 2021 - By 9 February 2021, the Coronavirus has killed 2,336,650 people worldwide and it has been predicted that this number continues to increase in year 2021. The study aimed to identify therapeutic approaches and drugs that can potentially be used as interventions in Coronavirus 2019 (COVID-19) management. A systematic scoping review was conducted. Articles reporting clinical evidence of therapeutic...

Apr 5th, 2021 - We aimed to investigate whether the stratification of outpatients with coronavirus disease 2019 (COVID-19) pneumonia by body mass index (BMI) can help predict hospitalization and other severe outcomes. We prospectively collected consecutive cases of community-managed COVID-19 pneumonia from March 1 to April 20, 2020, in the province of Bergamo and evaluated the association of overweight (25 kg/...

Apr 4th, 2021 - To determine whether hydroxychloroquine decreases the risk of adverse outcome in patients with mild-to-moderate COVID-19 at high risk of worsening. We conducted a multicentre randomized double-blind placebo-controlled trial evaluating hydroxychloroquine in COVID-19 patients with at least one of the following risk factors for worsening: need for supplemental oxygen, age ≥75 years, age between 60...

Apr 3rd, 2021 - Psoriasis is a chronic skin disease that needs continuous medical care. During COVID-19, delivering medical service was negatively affected. To describe the impact of COVID-19 on psoriasis healthcare delivery, management, and practice. This observational cross-sectional study was conducted on 197 dermatologists using a validated online questionnaire. The survey evaluated the effect of COVID-19 ...

Mar 31st, 2021 - Drug safety is generally established from clinical trials, by pharmacovigilance programs and during observational Phase IV safety studies according to drug intended or approved indications. The objective of this study was to estimate the risk of potential adverse drug events (ADE) associated with drugs repurposed for COVID-19 treatment in a large-scale population. Drug claims were used to calcu...

Mar 31st, 2021 - To understand medication, lifestyle, and clinical care changes by persons with RA during the first months (March through May 2020) of the COVID-19 pandemic in the US. Data were provided by adults with RA participating in FORWARD, The National Databank for Rheumatic Diseases, observational registry who answered COVID-19 web-based surveys in May 2020 and previously provided baseline (pre-COVID) c...

Mar 31st, 2021 - Herbal medicines, as a treatment method, have received a great deal of attention. The effects of two herbal medicines namely Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients were examined. A clinical trial with 100 suspected COVID-19 outpatients as participants was conducted. The participants were allocated randomly...

Mar 31st, 2021 - During the COVID-19 pandemic, the rush to scientific and political judgements on the merits of hydroxychloroquine was fuelled by dubious papers which may have been published because the authors were not independent from the practices of the journals in which they appeared. This example leads us to consider a new type of illegitimate publishing entity, 'self-promotion journals' which could be de...

Mar 31st, 2021 - Only a handful of FDA Emergency Use Authorizations exist for drug and biologic therapeutics that treat SARS-CoV-2 infection. Potential therapeutics include repurposed drugs, some with cardiac liabilities. We report on a chronic preclinical drug screening platform, a cardiac microphysiological system (MPS), to assess cardiotoxicity associated with repurposed hydroxychloroquine (HCQ) and azithrom...

Mar 31st, 2021 - The cause-and-effect relationship of QTc prolongation in Coronavirus disease 2019 (COVID-19) patients has not been studied well. We attempt to better understand the relationship of QTc prolongation in COVID-19 patients in this study. This is a retrospective, hospital-based, observational study. All patients with normal baseline QTc interval who were hospitalized with the diagnosis of COVID-19 i...

Mar 30th, 2021 - Hydroxychloroquine (HCQ) was one of the earliest drugs to be recommended for tackling the COVID-19 threat leading to its widespread usage across the world. We provide preliminary findings of the system, established in a tertiary care academic centre for the administration of HCQ prophylaxis to healthcare workers (HCW) based on Indian Council of Medical Research (ICMR) advisory. A dedicated clin...

Mar 29th, 2021 - To investigate the presence of white hat bias in Covid-19 treatment research by evaluating the effects of citation and reporting bias. Citation bias was investigated by assessing the degree of agreement between evidence provided by a remdesivir randomized controlled trial and its citing articles. The dissimilarity of outcomes derived from nonrandomized and randomized studies was tested by a met...

Mar 29th, 2021 - Current clinical evidences do not support any specific treatment against SARS-CoV-2. Chloroquine (CQ) and hydroxychloroquine (HCQ) are typically used in the treatment of rheumatoid arthritis, systemic lupus erythematosus and malaria; they have been considered for off-label and compassionate use in several countries against moderate to severe cases of COVID-19 and there's actually a massive dema...